Markets:

Overview

News

Currencies

International

Treasuries

Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

2.125 +0.305 (+16.76%)

Streaming Delayed Price Updated: 2:05 PM EST, Jan 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Prelude Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 Next >

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

December 16, 2025

Issued on behalf of Oncolytics Biotech Inc.

From Equity Insider

Via GlobeNewswire

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

December 06, 2025

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

November 26, 2025

From Schall Law

Via GlobeNewswire

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

November 19, 2025

From Schall Law

Via GlobeNewswire

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

November 19, 2025

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END

Via FinancialNewsMedia

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

November 19, 2025

From FN Media Group LLC

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 13, 2025

Via Benzinga

Prelude Therapeutics Inc. (NASDAQ:PRLD) Beats Q3 2025 Earnings Estimates and Extends Cash Runway ↗

November 12, 2025

Prelude Therapeutics beats Q3 2025 earnings estimates, extends cash runway into 2027, and advances its precision oncology pipeline.

Via Chartmill

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 12, 2025

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm

November 11, 2025

From The Schall Law Firm

Via Business Wire

In today's session, these stocks are experiencing unusual volume. ↗

November 05, 2025

Let's have a look at the stocks with an unusual volume in today's session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 04, 2025

Via Benzinga

Which stocks are experiencing notable movement on Tuesday? ↗

November 04, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.

Via Chartmill

On Tuesday, there are stocks with unusual volume. Let's take a look. ↗

November 04, 2025

Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Via Chartmill

Tuesday's session: top gainers and losers ↗

November 04, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 04, 2025

Via Benzinga

These stocks are gapping in today's session ↗

November 04, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Dow Dips Over 400 Points; Pfizer Earnings Top Estimates ↗

November 04, 2025

Via Benzinga

Topics Stocks

Tuesday's pre-market session: top gainers and losers ↗

November 04, 2025

The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 04, 2025

Via Benzinga

Prelude Therapeutics Announces Strategic Business Update

November 04, 2025

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

November 04, 2025

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

These stocks are moving in today's after hours session ↗

November 03, 2025

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 03, 2025

Via Benzinga

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

November 03, 2025

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Tuesday's session: top gainers and losers ↗

October 21, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

October 17, 2025

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Cuts Q2 Losses and Costs 13% ↗

August 14, 2025

Via The Motley Fool

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14, 2025

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

June 02, 2025

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.